Korean Circ J.  2017 Nov;47(6):864-867. 10.4070/kcj.2017.0302.

The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea

• Kim SJ

• KMID: 2396479
• DOI: http://doi.org/10.4070/kcj.2017.0302

Abstract

No abstract available.

MeSH Terms

Korea*
Myocardial Infarction*
Purinergic P2Y Receptor Antagonists*
Purinergic P2Y Receptor Antagonists

Reference

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494–502.

2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–2015.

3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–1057.

4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344–e426.

5. Green A, Pottegård A, Broe A, et al. Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ Open. 2016; 6:e010880.

6. Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016; 46:559–565.

7. Angerås O, Hasvold P, Thuresson M, Deleskog A. ÖBraun O. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. Scand Cardiovasc J. 2016; 50:99–107.

8. Sheikh Rezaei S, Geroldinger A, Heinze G, Reichardt B, Wolzt M. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014. Int J Cardiol. 2017; 235:61–66.

9. Larmore C, Effron MB, Molife C, et al. “Real-world” comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv. 2016; 88:535–544.

10. Kim C, Shin DH, Ahn CM, et al. The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean Health Insurance Review and Assessment data. Korean Circ J. 2017; 47:888–897.